Skip to main content

Advertisement

SpringerLink
Log in

A better prescription for drug-development financing

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

As the cost of drug development continues to rise and public markets shift their attention to companies with late-stage products, an increasing diversity of financing options are becoming available to biotech companies with early-stage clinical programs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: A comparison of biotech and pharmaceutical R&D productivity.
Figure 2: Clinical-stage development candidates.
Figure 3: Sources of biotech equity capital.
Figure 4: Value of biotech out-licensing deals.
Figure 5: Current (typical) deal terms by stage of development.
Figure 6
Figure 7: Example of a collaborative development financing structure.
Figure 8: Illustrative value creation through collaborative development financing.

References

  1. Kaitin, K.I. (ed.) Cost to develop new biotech products is estimated to average $1.2 billion. Tufts Center for the Study of Drug Development Impact Report, vol. 8 (Tufts Center for the Study of Drug Development, Boston, Massachusetts, November/December 2006)

    Google Scholar 

  2. Bouchie, A.J. Optioning your drugs. The Scientist 20, 76 (2006).

    Google Scholar 

  3. Schiff, L. & Murray, F. Biotechnology financing dilemmas and the role of special purpose entities. Nat. Biotechnol. 22, 271–277 (2004).

    Article  CAS  Google Scholar 

  4. Ransom, J. A reprise for collaborative financing in biotech. Nat. Biotechnol. 24, 873–874 (2006).

    Article  CAS  Google Scholar 

  5. <http://www.pharmadd.com/archives/July%202006/MM%20Deals%20Bring%20Value.asp>

  6. Longman, R. No dilution necessary: the promise of project financing. In Vivo 23, 12 (2005).

    Google Scholar 

Download references

Acknowledgements

The authors would like to thank Sam Hall of Symphony Capital LLC, who assisted in the preparation of this article.

Author information

Authors and Affiliations

  1. Mark Kessel is at Symphony Capital, 875 Third Avenue, 18th floor, New York, New York 10022, USA. mark@symphonycapital.com,

    Mark Kessel

  2. Frederick Frank is at Lehman Brothers, Inc., 745 Seventh Avenue, New York, New York 10019-6801, USA.,

    Frederick Frank

Authors
  1. Mark Kessel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick Frank
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kessel, M., Frank, F. A better prescription for drug-development financing. Nat Biotechnol 25, 859–866 (2007). https://doi.org/10.1038/nbt0807-859

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0807-859

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation